Earnings summaries and quarterly performance for MANNKIND.
Executive leadership at MANNKIND.
MC
Michael Castagna
Detailed
Chief Executive Officer
CEO
CP
Christopher Prentiss
Detailed
Chief Financial Officer
DT
David Thomson
Detailed
Executive Vice President, General Counsel and Secretary
DM
Dominic Marasco
Detailed
President, Endocrine Business Unit
LS
Lauren Sabella
Detailed
Executive Vice President, Operations
SS
Sanjay Singh
Detailed
Executive Vice President, Technical Operations
ST
Stuart Tross
Detailed
Executive Vice President, Chief People and Workplace Officer
Board of directors at MANNKIND.
Research analysts who have asked questions during MANNKIND earnings calls.
BF
Brandon Folkes
Rodman & Renshaw
5 questions for MNKD
Also covers: ACHV, ANIP, AVDL +12 more
Andreas Argyrides
Oppenheimer & Co. Inc.
4 questions for MNKD
Also covers: AQST, ARSP, CLSD +7 more
OB
Olivia Brayer
Cantor
4 questions for MNKD
Also covers: AMGN, AUPH, BMRN +9 more
AN
Anish Nikhanj
RBC Capital Markets
3 questions for MNKD
Also covers: APTO, CRMD, EXEL +6 more
Faisal Khurshid
Leerink Partners
3 questions for MNKD
Also covers: ABCL, ANIP, ASND +7 more
Yun Zhong
Wedbush Securities
3 questions for MNKD
Also covers: ASND, MRKR, PASG +2 more
AP
Anthony Petrone
Mizuho Group
2 questions for MNKD
Also covers: ADMA, ALC, AXGN +24 more
RR
Roanna Ruiz
Leerink
2 questions for MNKD
Also covers: CRMD, CYTK, ENTA +4 more
A
Aneesh
Truist Securities
1 question for MNKD
A
Anish
Truist Securities
1 question for MNKD
Recent press releases and 8-K filings for MNKD.
MannKind Discusses 2025 Performance, 2026 Outlook, and Pipeline Progress
MNKD
Guidance Update
Product Launch
New Projects/Investments
- MannKind reported Q4 and full year 2025 total revenues of nearly $350 million, representing a 46% annual growth rate, and projects 2026 revenue to exceed $450 million.
- The Phase 1 study for MNKD-201 (Nintedanib DPI) for IPF is progressing with 4 patients enrolled and 10 in screening for the 24-person study, with the first part expected to conclude within 30-45 days. Phase 2 enrollment is anticipated to begin in Q2 , with the program viewed as a blockbuster opportunity.
- The PDUFA date for Afrezza's pediatric approval is May 29th, with a planned launch in January 2027.
- FUROSCIX sales are expected to be driven by the hospital segment for heart failure and nephrology for chronic kidney disease, with significant potential from the upcoming auto-injector.
- Despite recent stock volatility related to United Therapeutics' Tyvaso soft mist inhaler, MannKind emphasizes the significant cash flow from Tyvaso DPI royalties ($700 million to $1 billion over several years) and its focus on internal pipeline growth.
1 day ago
MannKind Reports Strong 2025 Revenue, Provides 2026 Guidance, and Updates on Key Pipeline Programs
MNKD
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- MannKind reported Q4 and full year 2025 total revenues of nearly $350 million, representing a 46% annual growth rate, and projects 2026 revenue to climb above $450 million.
- Key drivers for 2026 revenue include Afrezza's pediatric expansion, FUROSCIX autoinjector approval, and royalties from Tyvaso DPI.
- The MNKD-201 (nintedanib DPI) program for IPF is progressing, with 4 patients enrolled and 10 in screening in the Phase 1 study, and Phase 2 enrollment expected to begin in Q2. This program is considered a blockbuster opportunity.
- The PDUFA target date for Afrezza pediatric approval is May 29th , and the ReadyFlow Autoinjector for FUROSCIX is anticipated to significantly expand its market.
- The company addressed the recent stock reaction to United Therapeutics' (UT) soft mist inhaler for Tyvaso, emphasizing that MannKind has strong near-term growth drivers from its own pipeline and expects continued revenue from Tyvaso DPI.
1 day ago
MannKind Reports Strong 2025 Revenue, Provides 2026 Guidance, and Updates on Pipeline Progress
MNKD
Earnings
Guidance Update
New Projects/Investments
- MannKind reported Q4 and full-year 2025 total revenues of nearly $350 million, representing a 46% annual growth rate.
- The company projects 2026 revenue to climb above $450 million, driven by Afrezza's pediatric expansion, O6 auto injector approval, and royalties from Tyvaso DPI.
- The MNKD-201 program for IPF has initiated its Phase 1 study in December, with 4 patients enrolled and 10 in screening, and Phase 2 is expected to begin enrolling patients early in Q2.
- The PDUFA date for Afrezza pediatric approval is May 29 , and the INHALE-first trial for naive pediatric patients is underway with 3-4 patients enrolled.
- Management addressed the recent stock reaction concerning United Therapeutics' potential soft mist inhaler for Tyvaso, stating that Tyvaso DPI is still expected to generate $700 million to $1 billion in cash flow over the next several years.
1 day ago
MannKind Discusses 2025 Financials, 2026 Outlook, and Pipeline Progress
MNKD
Guidance Update
Product Launch
New Projects/Investments
- MannKind reported Q4 and full year 2025 total revenues of nearly $350 million, representing a 46% annual growth rate, and projects 2026 revenue to climb above $450 million.
- The Phase 1 study for MNKD-201 (Nintedanib DPI) for IPF, a potential blockbuster opportunity, initiated in December 2025, is progressing with 4 patients enrolled and 10 in screening for a 24-person study; Phase 2 enrollment is expected in Q2 2026.
- The PDUFA date for Afrezza's pediatric approval is May 29th, with a planned launch in January 2027.
- Key drivers for FUROSCIX sales in 2026 include expansion into the hospital segment and targeting nephrologists for chronic kidney disease, with future potential from an auto-injector.
- The recent stock reaction to UT's soft mist inhaler announcement was attributed to investors unwinding hedge positions, but MannKind's CEO highlighted strong near-term prospects for 2026, 2027, and 2028 from other growth drivers.
1 day ago
MannKind Reports Record Q4 2025 Revenue and Outlines 2026 Growth Drivers
MNKD
Earnings
M&A
Product Launch
- MannKind reported record quarterly revenue of $112 million in Q4 2025, representing a 46% increase year-over-year, with full-year 2025 total revenue reaching $349 million, up 22%.
- The company completed the acquisition of scPharmaceuticals in Q4 2025, integrating FUROSCIX, which contributed $23.3 million in net sales for the quarter, an increase of 91% year-over-year.
- Key upcoming catalysts include PDUFA dates for the Afrezza pediatric indication on May 29 and the FUROSCIX ReadyFlow Autoinjector on July 26, positioning the company for potential growth.
- MannKind projects a clear path to over $450 million revenue run rate in 2026 and expects to receive over $350 million in Tyvaso DPI royalties over the next 36 months.
1 day ago
MannKind Reports Record Q4 2025 Revenue and Outlines Key Growth Catalysts
MNKD
Earnings
Product Launch
Guidance Update
- MannKind reported record quarterly revenue of $112 million in Q4 2025 and nearly $350 million in total revenue for the full year 2025, reflecting a 46% compound annual growth rate over the past five years.
- Key upcoming catalysts include PDUFA dates for the Afrezza pediatric indication on May 29 and the FUROSCIX ReadyFlow Autoinjector on July 26.
- FUROSCIX net sales reached $23.3 million in Q4 2025 (up 91% year-over-year) and $70.4 million for the full year 2025, with a projected 2026 sales range of $100 million to $120 million.
- The company anticipates a revenue run rate exceeding $450 million in 2026 and plans to invest up to an additional $40 million to support upcoming product launches.
- The long-term supply agreement with United Therapeutics is expected to generate over $400 million in revenue from minimum orders over the next six years and over $350 million in royalties over the next 36 months.
1 day ago
Mannkind Reports Record Q4 2025 Revenue and Provides Key Product Updates
MNKD
Earnings
M&A
Product Launch
- Mannkind reported record quarterly revenue of $112 million for Q4 2025 and total revenue of $349 million for the full year 2025.
- The company completed the scPharmaceuticals acquisition, strengthening its cardiometabolic franchise with FUROSCIX®.
- Key upcoming catalysts include PDUFA dates for Afrezza® Pediatric Indication on May 29, 2026, and FUROSCIX ReadyFlow™ Autoinjector on July 26, 2026.
- For Q4 2025, GAAP Net Loss was $(15.9) million, while Non-GAAP Adjusted Net Income was $1.5 million.
1 day ago
MannKind Reports Record Q4 and Full Year 2025 Revenue, Highlights Product Growth and Upcoming Catalysts
MNKD
Earnings
Revenue Acceleration/Inflection
Product Launch
- MannKind reported record quarterly revenue of $112 million in Q4 2025, a 46% increase from the prior year quarter, contributing to a full year 2025 total revenue of $349 million, up 22%.
- Key product performance in Q4 2025 included FUROSCIX net sales of $23.3 million (up 91% year-over-year) and Afrezza net US sales of $22.3 million (up 22% year-over-year). For the full year 2025, FUROSCIX generated $70.4 million and Afrezza $74.6 million.
- The company anticipates significant catalysts with PDUFA dates for the Afrezza pediatric indication on May 29 and the FUROSCIX ReadyFlow Autoinjector on July 26, and projects a clear path to over $450 million revenue run rate in 2026.
- The long-term supply agreement with United Therapeutics for Tyvaso DPI has 6 years remaining, with minimum orders expected to deliver over $400 million in revenue and a revenue floor of approximately $50 million per year through 2031.
1 day ago
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MNKD
Earnings
M&A
Product Launch
- MannKind Corporation reported total revenues of $112 million for Q4 2025, a 46% increase compared to Q4 2024, and $349 million for the full year 2025, up 22% from 2024.
- Key product net sales for Q4 2025 included Furoscix® at $23 million, a 91% increase from Q4 2024, and Afrezza® at $23 million, a 25% increase from Q4 2024.
- The company reported a net loss of $(15.9) million and basic EPS of $(0.05) for Q4 2025, and net income of $5.9 million and basic EPS of $0.02 for the full year 2025.
- MannKind successfully completed the acquisition of scPharmaceuticals Inc. on October 7, 2025, and held $176 million in cash, cash equivalents, and investments as of December 31, 2025.
- Significant upcoming milestones include PDUFA dates for Afrezza pediatric indication on May 29, 2026, and Furoscix ReadyFlow™ Autoinjector on July 26, 2026.
1 day ago
MannKind Announces FDA Approval for Updated Afrezza Label
MNKD
- MannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Prescribing Information for Afrezza® (insulin human) Inhalation Powder.
- This update revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens, providing clearer guidance for healthcare providers.
- The revised dosing recommendations, supported by clinical trials, are intended to facilitate a clinically appropriate and safe transition for adult patients initiating Afrezza.
Jan 26, 2026, 11:05 AM
Quarterly earnings call transcripts for MANNKIND.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more